Mycobacterial immunotherapy for prostate cancer: where can we go from here?

Nature Reviews Urology, Published online: 29 January 2020; doi:10.1038/s41585-020-0283-2The effects of mycobacteria in prostate cancer have not been fully elucidated. Results of early studies indicated that mycobacterial immunotherapy conferred a survival benefit in patients with advanced prostate cancer, and recent evidence supports the safety and efficacy of new mycobacterial agents in many malignancies; thus, modern, carefully designed, randomized controlled trials of mycobacterial immunotherapy for prostate cancer could be warranted.

Source: Nature Reviews Urology - January 28, 2020 Category: Urology & Nephrology Authors: Vasilis Stavrinides Angus Dalgleish John P. Copier Caroline M. Moore Source Type: research